Summit Securities Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Summit Securities Group’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300	Closed	-$181K	–	539
2019 Q4	$181K	Buy	+300	New	+$1.74K	0.01%	410

Summit Securities Group's ACHN Position: Q1 2020 in Review

Summit Securities Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 20,000 shares — an estimated $121K sold.

Summit Securities Group first reported a position in ACHN in Q4 2019 and held it in 1 quarter. The position peaked at $121K in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

Summit Securities Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Summit Securities Group sold 20,000 Achillion Pharmaceuticals shares in Q1 2020, an estimated $121K.
Summit Securities Group first reported a position in Achillion Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Summit Securities Group's Achillion Pharmaceuticals position peaked at $121K in Q4 2019.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Summit Securities Group's 13F filing for Q1 2020, filed 28 Apr 2020.